Citations

Clear

6273 citation(s) found for "To, Andrew".

Ink-Spiring Innovations: 3D Bioprinting Skin Models for Disease Discovery
Torigoe, Rafaela Mayumi Simoes , Revzin, Alexander , Wyles, Saranya P. , Simoes Torigoe, Rafaela Mayumi , Badley, Andrew, Wyles, Saranya, Badley, Andrew D.

Mayo Clinic

Regenerative Medicine | January 5, 2024 | Volume: 19 | Issue: 2 | Pages: 65-68

10.2217/rme-2023-0216 | PMID 38179985 Get It

Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Li, Yafang , Xiao, Xiangjun , Li, Jianrong , Han, Younghun , Cheng, Chao , Fernandes, Gail , Slewitzke, Shannon E. , Rosenberg, Susan M. , Zhu, Meng , Byun, Jinyoung , McKay, James , Lam, Stephen , Chen, Chu , Bojesen, Stig E. , Landi, Maria Teresa , Risch, Angela , Wichmann, H-Erich , Goodman, Gary E. , Field, John K. , Shete, Sanjay , Liu, Geoffrey , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan , Purrington, Kristen S. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Xia, Jun , Fernandes, Gail F , Bossé, Yohan , McKay, James , Albanes, Demetrius , Lam, Stephen , Tardón, Adonina , Chen, Chu , Bojesen, Stig E , Landi, Maria T , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Wichmann, H-Erich , Christiani, David C. , Rennert, Gad , Arnold, Susanne M , Goodman, Gary E , Field, John K , Davies, Michael P A , Shete, Sanjay , Marchand, Loïc Le , Liu, Geoffrey , Hung, Rayjean J , Andrew, Angeline S , Kiemeney, Lambertus A , Sun, Ryan , Zienolddiny, Shanbeh , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E , Cox, Angela , Hong, Yun‐Chul , Lazarus, Philip J. , Schabath, Matthew B , Aldrich, Melinda C , Schwartz, Ann G , Gorlov, Ivan , Purrington, Kristen S , Yang, Ping , Liu, Yanhong , Wilson, Richard K , Pinney, Susan M , Mandal, Diptasri , Willey, James C , Brennan, Paul , Xia, Jun , Shen, Hongbing , Amos, Christopher I , Han, Younghun , Cheng, Chao , Byun, Jinyoung , Bossé, Yohan , Albanes, Demetrius , Tardón, Adonina , Johansson, Mattias , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Marchand, Loı̈c Le , Hung, Rayjean J. , Kiemeney, Lambertus A. , Zienolddiny, Shanbeh , Cox, Angela , Schabath, Matthew B. , Yang, Ping , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Willey, James C. , Shen, Hongbing , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 5, 2024 | Volume: 33 | Issue: 3 | Pages: 389-399

10.1158/1055-9965.epi-23-0613 | PMID 38180474 Get It

Abstract Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P < 5 × 10−8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Hand-Held Echocardiography by Advanced Practice Providers in Patients with Congestive Heart Failure
Tagle-Cornell, Maria Cecilia , Novais, Barbara S., Wen, Songnan , Shipman, Justin , Mandale, Deepa, Flom, Andrew P., Sahnan, Sandeep, Kriz, Lindsey M., Alland, Michelle L., Bird, Christen W., Naqvi, Tasneem Z. , Shipman, Justin N, Mandale, Deepa R, Sahnan, Sandeep K, Naqvi, Tasneem Z

Mayo Clinic

Journal of Clinical Medicine | January 5, 2024 | Volume: 13 | Issue: 2 | Pages: 312

10.3390/jcm13020312 | PMID 38256445 Get It

Objectives: The performed hand-held echocardiography (HHE) was evaluated and interpreted by trained advanced practice providers (APPs) on hospitalized CHF patients for image quality and interpretation by comparing with expert echocardiographer and SE findings. Background: Congestive heart failure (CHF) is associated with increased hospital admissions and mortality. While a standard echocardiogram (SE) is the gold standard for cardiac assessment, it is not readily available. Hospitalized CHF patients require rapid assessment for expedited treatment. Methods: Over 6 months, five trained APPs performed HHE on hospitalized CHF patients and interpreted: (a) left ventricular (LV) size, (b) LV ejection fraction (LVEF), and (c) right atrial pressure (RAP). The study echocardiographer reviewed and blindly interpreted the HHE images and compared them with APPs and SE findings. Kappa statistics determined the degree of agreement between APPs and the study echocardiographer’s interpretation of the HHE images and SE. Results: A total of 80 CHF patients (age 73 ± 14 years, 58% males; LVEF (by SE) 45 ± 19%; 36.3% body mass indexes ≥ 30 kg/m2) were enrolled. HHE interpretation by APPs had a good agreement for LVEF (kappa 0.79) with the study echocardiographer and SE (kappa 0.74) and a good agreement for RAP (kappa 0.67) with the study echocardiographer. The correlation between the absolute LVEF interpretation by the study echocardiographer on HHE and SE was r = 0.88 (p < 0.0001). Conclusions: Trained APPs obtained diagnostic-quality HHE images and interpreted the LV function and RAP in CHF patients in good agreement with the study echocardiographer. LVEF by HHE correlated with LVEF by SE. Our study suggests trained APPs can use HHE to evaluate LVEF and RAP in CHF patients, leading to expedited and optimized treatment.
Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.

Mayo Clinic

Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available

10.1128/jvi.01791-23 | PMID 38168672 Get It

ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.
PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION‐FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB
Abeykoon, Jithma P. , Gustine, Joshua , Zanwar, Saurabh , Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Xu, Lian, Ansell, Stephen M. , Kapoor, Prashant , Palomba, Lia, Castillo, Jorge J. , Yang, Guang , Hunter, Zachary R. , Advani, Ranjana H. , Gertz, Morie A. , Treon, Steven P.

Mayo Clinic

HemaSphere | December 31, 2023 | Volume: 3 | Issue: S1 | Pages: 194-195

10.1002/j.2572-9241.2019.tb00084.x Get It

Background:Ibrutinib is approved in Europe and the US for the treatment of Waldenstrom macroglobulinemia (WM) with a median progression‐free survival (PFS) measured on several years. As PFS is commonly used for drug approval by regulatory entities, there is an unmet need of reliable surrogate markers for PFS that could help accelerating such process. This is of importance with novel BTK inhibitors currently in clinical trials.Aims:We hypothesized that the depth of response at 6 months can be predictive of PFS in patients with WM treated with the BTK inhibitor ibrutinib.Methods:We evaluated our hypothesis in two separate cohorts of WM patients treated with ibrutinib. The learning cohort was composed by participants of two prospective clinical trials at Dana‐Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center and Stanford Cancer Center. The validation cohort was composed by consecutive WM patients treated with ibrutinib off clinical trial at DFCI and Mayo Clinic. Categorical responses at 6 months were assessed based on criteria from the 6thInternational Workshop for WM. PFS6 was defined as the time from the 6‐month response assessment until progression of disease or death from any cause. PFS6 curves were generated using the Kaplan‐Meier method and compared using the log‐rank test. Cox proportional hazard regression models were fitted for PFS6. Pvalues <0.05 were considered statistically significant.Results:The learning and validation cohorts were composed by 92 and 190 WM patients treated with ibrutinib, repsectively. There were no statistical differences between cohorts with regards to age, sex, serum IgM level, hemoglobin level, bone marrow involvement, prior treatment status, and MYD88 and CXCR4 mutational status (p>0.05 for all variables). The rates of partial response (PR) or better at 6 months in the learning and validation cohorts were 63% (54/86) and 72% (114/159), respectively (p = 0.15). The median PFS6 was not reached in the learning cohort and was 53 months (95% CI 44‐not reached) in the validation cohort. In the learning cohort, the median PFS6 for patients who attained a PR or better at 6 months was not reached, while for the patients who did not attained PR at 6 months was 48 months (95% CI 33‐not reached). The 3‐year PFS rate for patients who attained a PR or better at 6 months was 83% (95% CI 68–91%), while for patients who did not attained PR at 6 months was 58% (95% CI 33–76%) (Figure, left, log‐rank p = 0.02). Attaining PR or better at 6 months was associated with a hazard ratio (HR) or progressing or dying of 0.37 (95% CI 0.16–0.87; p = 0.02).In the validation cohort, the median PFS6 for patients who attained a PR or better at 6 months was 53 months (95% CI 44‐not reached), while for the patients who did not attained PR at 6 months was 32 months (95% CI 22‐not reached). The 3‐year PFS rate for patients who attained a PR or better at 6 months was 79% (95% CI 67–87%), while for patients who did not attained PR at 6 months was 50% (95% CI 26–70%) (Figure, right, log‐rank p = 0.04). Attaining PR or better at 6 months was associated with a hazard ratio (HR) or progressing or dying of 0.46 (95% CI 0.22–0.98; p = 0.04). Age, sex, serum IgM level, hemoglobin level, bone marrow involvement and prior treatment status were not prognostic of PFS6 in both cohorts.Summary/Conclusion:Attaining a PR or better at 6 months to ibrutinib is associated with longer median PFS and higher rates of 3‐year PFS in WM patients. Depth of response at 6 months could serve as a surrogate for PFS in clinical trials evaluating BTK inhibitors in WM patients.image
Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Sandau, Ursula S. , Magaña, Setty M. , Costa, Júlia , Nolan, John P. , Ikezu, Tsuneya , Vella, Laura J. , Jackson, Hannah K. , Palacio, Paola Loreto , Hill, Andrew F. , Keuren‐Jensen, Kendall Van , McFarland, Trevor J. , Palade, Joanna , Sribnick, Eric A. , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Saugstad, Julie A. , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task, Moreira, Lissette Retana , Hill, Andrew F , Quinn, Joseph F , Van Keuren-Jensen, Kendall R , McFarland, Trevor J , Sribnick, Eric A , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Yang, You , Falcón-Perez, Juan Manual , Nieuwland, Rienk , Saugstad, Julie A , Ikezu, Tsuneya , Quinn, Joseph F. , Palade, Joanna , You, Yang , Falcón‐Pérez, Juan Manuel , Nieuwland, Rienk , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task

Mayo Clinic

Journal of Extracellular Vesicles | December 29, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/jev2.12397 | PMID 38158550 Get It

Abstract Cerebrospinal fluid (CSF) is a clear, transparent fluid derived from blood plasma that protects the brain and spinal cord against mechanical shock, provides buoyancy, clears metabolic waste and transports extracellular components to remote sites in the brain. Given its contact with the brain and the spinal cord, CSF is the most informative biofluid for studies of the central nervous system (CNS). In addition to other components, CSF contains extracellular vesicles (EVs) that carry bioactive cargoes (e.g., lipids, nucleic acids, proteins), and that can have biological functions within and beyond the CNS. Thus, CSF EVs likely serve as both mediators of and contributors to communication in the CNS. Accordingly, their potential as biomarkers for CNS diseases has stimulated much excitement for and attention to CSF EV research. However, studies on CSF EVs present unique challenges relative to EV studies in other biofluids, including the invasive nature of CSF collection, limited CSF volumes and the low numbers of EVs in CSF as compared to plasma. Here, the objectives of the International Society for Extracellular Vesicles CSF Task Force are to promote the reproducibility of CSF EV studies by providing current reporting and best practices, and recommendations and reporting guidelines, for CSF EV studies. To accomplish this, we created and distributed a world‐wide survey to ISEV members to assess methods considered ‘best practices’ for CSF EVs, then performed a detailed literature review for CSF EV publications that was used to curate methods and resources. Based on responses to the survey and curated information from publications, the CSF Task Force herein provides recommendations and reporting guidelines to promote the reproducibility of CSF EV studies in seven domains: (i) CSF Collection, Processing, and Storage; (ii) CSF EV Separation/Concentration; (iii) CSF EV Size and Number Measurements; (iv) CSF EV Protein Studies; (v) CSF EV RNA Studies; (vi) CSF EV Omics Studies and (vii) CSF EV Functional Studies.
Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight
Gemelli, Marco , Doulamis, Ilias P. , Tzani, Aspasia , Rempakos, Athanasios, Guariento, Alvise , Spiliopoulos, Kyriakos , Asleh, Rabea , Duque, Ernesto Ruiz , Briasoulis, Αlexandros , Guariento, Alvise , Spiliopoulos, Kyriakos , Asleh, Rabea , Duque, Ernesto Ruiz , Briasoulis, Alexandros , Kampaktsis, Polydoros Ν. , Álvarez, Paulino , Xanthopoulos, Andrew V. , Giamouzis, Grigorios

Mayo Clinic

Journal of Personalized Medicine | December 29, 2023 | Volume: 14 | Issue: 1 | Pages: 52

10.3390/jpm14010052 | PMID 38248753 Get It

(1) Background: Heart failure is an extremely impactful health issue from both a social and quality-of-life point of view and the rate of patients with this condition is destined to rise in the next few years. Transplantation remains the mainstay of treatment for end-stage heart failure, but a shortage of organs represents a significant problem that prolongs time spent on the waiting list. In view of this, the selection of donor and recipient must be extremely meticulous, considering all factors that could predispose to organ failure. One of the main considerations regarding heart transplants is the risk of graft rejection and the need for immunosuppression therapy to mitigate that risk. In this study, we aimed to assess the characteristics of patients who need immunosuppression treatment for rejection within one year of heart transplantation and its impact on mid-term and long-term mortality. (2) Methods: The United Network for Organ Sharing (UNOS) Registry was queried to identify patients who solely underwent a heart transplant in the US between 2000 and 2021. Patients were divided into two groups according to the need for anti-rejection treatment within one year of heart transplantation. Patients’ characteristics in the two groups were assessed, and 1 year and 10 year mortality rates were compared. (3) Results: A total of 43,763 patients underwent isolated heart transplantation in the study period, and 9946 (22.7%) needed anti-rejection treatment in the first year. Patients who required treatment for rejection within one year after transplant were more frequently younger (49 ± 14 vs. 52 ± 14 years, p < 0.001), women (31% vs. 23%, p < 0.001), and had a higher CPRA value (14 ± 26 vs. 11 ± 23, p < 0.001). Also, the rate of prior cardiac surgery was more than double in this group (27% vs. 12%, p < 0.001), while prior LVAD (12% vs. 11%, p < 0.001) and IABP (10% vs. 9%, p < 0.01) were more frequent in patients who did not receive anti-rejection treatment in the first year. Finally, pre-transplantation creatinine was significantly higher in patients who did not need treatment for rejection in the first year (1.4 vs. 1.3, p < 0.01). Most patients who did not require anti-rejection treatment underwent heart transplantation during the new allocation era, while less than half of the patients who required treatment underwent transplantation after the new allocation policy implementation (65% vs. 49%, p < 0.001). Patients who needed rejection treatment in the first year had a higher risk of unadjusted 1 year (HR: 2.25; 95% CI: 1.88–2.70; p < 0.001), 5 year (HR: 1.69; 95% CI: 1.60–1.79; p < 0.001), and 10 year (HR: 1.47; 95% CI: 1.41–1.54, p < 0.001) mortality, and this was confirmed at the adjusted analysis at all three time-points. (4) Conclusions: Medical treatment of acute rejection was associated with significantly increased 1 year mortality compared to patients who did not require anti-rejection therapy. The higher risk of mortality was confirmed at a 10 year follow-up. Further studies and newer follow-up data are required to investigate the role of anti-rejection therapy in the heart transplant population.
Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up
Stan, Daniela , Kim, Julian O. , Schaid, Daniel J. , Carlson, Erin E. , Kim, Christina , Couch, Fergus J. , Vachon, Celine M. , Cooke, Andrew , Goldenberg, Benjamin A. , Pruthi, Sandhya , Couch, Fergus J. , Stan, Daniela L , Kim, Christina A , Sinnwell, Jason P , Vachon, Celine M. , Cooke, Andrew L , Goldenberg, Benjamin , Pruthi, Sandhya , Sinnwell, Jason P.

Mayo Clinic

Cancer Prevention Research | December 28, 2023 | Volume: 17 | Issue: 2 | Pages: 77-84

10.1158/1940-6207.capr-23-0256 | PMID 38154464 Get It

Abstract Refinement of breast cancer risk estimates with a polygenic-risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined breast cancer risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and 2-year follow-ups. Of 151 participants, 58 (38.4%) initiated ET, and 22 (14.6%) discontinued ET by 2 years; 42 (27.8%) and 36 (23.8%) participants were using ET at 1- and 2-year follow-ups, respectively. At the 2-year follow-up, 39% of participants with a lifetime breast cancer risk of 40.1% to 100.0%, 18% with a 20.1% to 40.0% risk, and 16% with a 0.0% to 20.0% risk were taking ET (overall P = 0.01). Moreover, 40% of participants whose breast cancer risk increased by 10% or greater with addition of the PRS to a traditional breast cancer-risk model were taking ET versus 0% whose risk decreased by 10% or greater (P = 0.004). QOL was similar for participants taking or not taking ET at 1- and 2-year follow-ups, although most who discontinued ET did so because of adverse effects. However, these QOL results may have been skewed by the long interval between QOL surveys and lack of baseline QOL data. PRS-informed breast cancer prevention counseling has a lasting, but waning, effect over time. Additional follow-up studies are needed to address the effect of PRS on ET adherence, ET-related QOL, supplemental breast cancer screening, and other risk-reducing behaviors. Prevention Relevance: Risk-reducing medications for breast cancer are considerably underused. Informing women at risk with precise and individualized risk assessment tools may substantially affect the incidence of breast cancer. In our study, a risk assessment tool (IBIS-polygenic-risk score) yielded promising results, with 39% of women at highest risk starting preventive medication.
Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App
Fagan, Andrew , Gallagher, Mary Leslie, Mousel, Travis, Davis, Brian , Puri, Puneet, Anstey, Jacob, Tiede, David, Kraus, Asaf, Bajaj, Jasmohan S. , Bajaj, Jasmohan S , Fuchs, Michael A. , Puri, Puneet, Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | December 28, 2023 | Volume: 119 | Issue: 5 | Pages: 977-981

10.14309/ajg.0000000000002646 | PMID 38153339 Get It

Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls (N = 13) and cirrhosis patients on lactulose/not on lactulose (n = 33) were trained on the app. They entered self-reported BSS (self-BSS) with AI-BSS communicated. Lactulose dose changes were tracked. A subset (n = 12) was retested with AI communication blocked. Most subjects were comfortable with the app. Self/AI-BSS and lactulose dose/AI-BSS correlation increased with app use. AI-BSS communications improved insight into self-BSS over time. Dieta app to gauge stool AI characteristics was acceptable and increased insight into lactulose dose and BSS in cirrhosis.
Relationship between Arterial Transit Time and Framingham Risk Score in the U.S. POINTER lifestyle intervention trial
Hong, Sarah Y., Kim, Dong‐Hoon , Borowski, Bret, Gordineer, Leslie, Woolard, Nancy , Lovato, Laura, Masdeu, Joseph C. , Oh, Hwamee , Aggarwal, Neelum T. , Carrillo, Marı́a C., Snyder, Heather M. , Whitmer, Rachel A. , Landau, Susan, Group, U.S. POINTER Study, Jung, Youngkyoo , Vemuri, Prashanthi , Jack, Clifford R. , Koeppe, Robert A. , Lockhart, Samuel N. , Harrison, Theresa M. , Espeland, Mark Andrew , Harvey, Danielle , Toga, Arthur W. , Masdeu, Joseph C , Gitelman, Darren R. , Baker, Laura D. , DeCarli, Charles , Group, U.S. POINTER Study

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083207 Get It

AbstractBackgroundThe U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a two‐year randomized controlled trial designed to evaluate the effects of lifestyle interventions on older adults aged 60‐79 years. The POINTER Imaging ancillary study employs arterial spin labeling (ASL) magnetic resonance imaging (MRI) with two inversion times, enabling the mapping of arterial transit time (ATT) and the investigation of its relationship with dementia risk factors. This study examines the effect of the Framingham Risk Score (FRS) on ATT, which provides hemodynamic information on the cerebral vasculature.MethodA subset of POINTER Imaging participants (n = 134; F/M = 81/53; age = 68.1±5.1; FRS = 11.3±10.4) from two imaging sites underwent two ASL MRI scans during the baseline session. Two 3D Pulsed ASL scans were obtained with TI1 of 790ms and TI2 values of 2000ms or 2750ms, providing delay times (between labeling and imaging) of 1210ms or 1960ms. ATT, the time required for blood to travel from the neck to the tissue, was estimated in the range of 1210ms and 1960ms using a kinetic model (Figure 1). ATT maps were normalized to a standard space, and a voxel‐wise linear regression (ATT∼age+sex+log(FRS)) was performed on ATT maps in gray matter to assess the effect of FRS on ATT. To control false positives, clusters smaller than 1.4ml were removed based on a simulation with α = 0.05.ResultFigure 2 depicts three clusters found in the occipital, precuneus and frontal gray matter regions, all of which demonstrate a positive relationship between ATT and log(FRS). Participants with higher FRS exhibit prolonged mean ATT values in the clusters as shown in Figure 3. After stratifying into sex groups, both groups show the same direction.ConclusionAlthough the detectable range of ATT with two ASL scans was limited, the analysis suggests that an increased risk of cardiovascular disease, as quantified by the Framingham Risk Score, can serve as an indicator of potential cerebrovascular disease leading to prolonged ATT, which is associated with arterial stiffness, and vascular resistance. The clusters demonstrating the association between FRS and ATT are the brain regions that may have heightened vulnerability to vascular risk factors, according to previous studies.